Sugi Predict

Sugi Predict / Compounds / SCHEMBL926809

SCHEMBL926809

SCHEMBL926809

COC(=O)Cc1ccc(O)c(F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 5/20 0.66
▸ ALDH1A1 P00352 2/20 0.66
▸ GFER P55789 1/20 0.66
▸ HSP90AB1 P08238 1/20 0.53
▸ CYP4F2 P78329 1/20 0.50
▸ CYP4A11 Q02928 1/20 0.50
▸ TSHR P16473 3/20 0.46
▸ NFKB1 P19838 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ HPGD P15428 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ YWHAG P61981 1/20 0.45
▸ PDK2 Q15119 1/20 0.45
▸ MIF P14174 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SLC7A5 Q01650 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30154442 1.00 GAA (0.66) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL30696815 0.86 GAA (0.61) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL2981679 0.86 GAA (0.61) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL30639470 0.86 ALDH1A1 (0.56) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL1717077 0.86 ALDH1A1 (0.56) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL29446278 0.84 GAA (0.72) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL3668882 0.84 GAA (0.72) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL29255156 0.84 ALDH1A1 (0.51) GAAALDH1A1GFERHSP90AB1CYP4F2
SCHEMBL226654 0.83 YWHAG (0.50) GAAALDH1A1GFERCYP4F2CYP4A11
SCHEMBL3683799 0.83 ALOX5 (0.51) GAAALDH1A1GFERTSHRMIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665458-A1 INHIBITING ALPHA V BETA8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 — — EP disclosed
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 — — US disclosed
EP-4461355-A2 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2024-11-13 — — EP disclosed
WO-2024173572-A1 INHIBITING α vβ8 INTEGRIN MORPHIC THERAPEUTIC, INC. (US) 2024-08-22 — — WO disclosed
US-20240262811-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2024-08-08 — — US disclosed
EP-4359381-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-05-01 — — EP disclosed
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CORNELL UNIVERSITY (US) 2024-04-30 — — US disclosed
CN-117858865-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 — — CN disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-5328921-A Antagonist of platelet activating factor AMERICAN CYANAMID COMPANY (US) 1994-07-12 — — US disclosed
US-5208247-A Antianaphylactic agents or septic shock AMERICAN CYANAMID COMPANY (US) 1993-05-04 — — US disclosed
EP-0530444-A1 Aryl, amide, imide, and carbamate pyridine antagonists of platelet activating factor AMERICAN CYANAMID COMPANY (US) 1993-03-10 — — EP disclosed
CN-1069025-A The aryl of platelet activating factor, acid amides, imide and carbamate pyridine antagonists AMERICAN CYANAMID CO (US) 1993-02-17 — — CN disclosed
US-4973697-A 2-halopyridine-6-sulfonic acid and its salt ONODA CEMENT CO., LTD. (JP) 1990-11-27 — — US disclosed
EP-0393462-A2 2-halopyridine-6-sulfonic acid and its salt ONODA CEMENT COMPANY, LTD. (JP) 1990-10-24 — — EP disclosed
US-4918092-A Leukotriene antagonists MERCK FROSST CANADA, INC. (CA) 1990-04-17 — — US disclosed
US-4820867-A ANTIALLERGENS MERCK FROSST CANADA, INC. (CA) 1989-04-11 — — US disclosed
EP-0123541-B1 LEUKOTRIENE ANTAGONISTS MERCK FROSST CANADA INC. (CA) 1987-07-22 — — EP disclosed
EP-0123541-A1 Leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1984-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CALCOCO2, MDN1, MBNL1 GAA 4698/4885ALDH1A1 4582/4885GFER 229/4885
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC GAA 1357/4885ALDH1A1 4185/4885GFER 3519/4885
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB GAA 572/4885ALDH1A1 848/4885GFER 1871/4885
US-20240262811-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GIPR, GCGR GAA 850/4885ALDH1A1 3087/4885GFER 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.